Review





Similar Products

full-length human ar cdna or protein sequences  (GenScript corporation)
90
GenScript corporation full-length human ar cdna or protein sequences
Full Length Human Ar Cdna Or Protein Sequences, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/full-length human ar cdna or protein sequences/product/GenScript corporation
Average 90 stars, based on 1 article reviews
full-length human ar cdna or protein sequences - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombinant full-length human ar and erα protein  (Creative BioMart)
90
Creative BioMart recombinant full-length human ar and erα protein
Relative AR/ER expression in primary and metastatic ER+ breast cancers. A, Bar chart of the percentage of AR staining intensity in <t>ER</t> weak (+), intermediate (2+), and strong (3+) tumors in IHC cohort. The intensity of nuclei immunoreactivity was assessed semiquantitatively on a scale of 0 to 3 (none, weak, intermediate, and strong). B, Distribution of AR/ER in IHC cohort (n = 68). Expressions were quantified using IHC scores, positive cell percentage × intensity. C, Distribution of AR/ER in TCGA breast cancer cohort (n = 347). The reverse phase protein array was used to test AR and <t>ER</t> <t>protein</t> levels. D, Violin plot of AR/ER level in primary and metastatic breast cancer. Bars are presented as 25th percentile (bottom quartile), median, and 75th percentile (top quartile). AR/ER is higher in metastatic cancer than in primary cancer (primary vs. metastatic, median 0.047 vs. 0.689, unpaired two-tailed Student t test, P = 0.0001). E and F, Kaplan–Meier survival curves displaying the estimated survival probability for two different groups (AR/ER high vs. low) of metastatic breast cancer. Patients with metastatic breast cancer (n = 97) subsequently treated with endocrine therapy were included in the analysis. Patients with AR/ER-high or -low groups were separated by median of AR/ER level in the cohort. The number of events (total deaths in each group) is indicated. Patients with lower AR/ER levels have a more favorable prognosis compared with patients who have higher AR/ER levels. E, Progression-free survival. F, Overall survival. The log-rank test indicates a significant difference between the survival curves.
Recombinant Full Length Human Ar And Erα Protein, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant full-length human ar and erα protein/product/Creative BioMart
Average 90 stars, based on 1 article reviews
recombinant full-length human ar and erα protein - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombinant full length human ar  (Creative BioMart)
92
Creative BioMart recombinant full length human ar
Relative AR/ER expression in primary and metastatic ER+ breast cancers. A, Bar chart of the percentage of AR staining intensity in <t>ER</t> weak (+), intermediate (2+), and strong (3+) tumors in IHC cohort. The intensity of nuclei immunoreactivity was assessed semiquantitatively on a scale of 0 to 3 (none, weak, intermediate, and strong). B, Distribution of AR/ER in IHC cohort (n = 68). Expressions were quantified using IHC scores, positive cell percentage × intensity. C, Distribution of AR/ER in TCGA breast cancer cohort (n = 347). The reverse phase protein array was used to test AR and <t>ER</t> <t>protein</t> levels. D, Violin plot of AR/ER level in primary and metastatic breast cancer. Bars are presented as 25th percentile (bottom quartile), median, and 75th percentile (top quartile). AR/ER is higher in metastatic cancer than in primary cancer (primary vs. metastatic, median 0.047 vs. 0.689, unpaired two-tailed Student t test, P = 0.0001). E and F, Kaplan–Meier survival curves displaying the estimated survival probability for two different groups (AR/ER high vs. low) of metastatic breast cancer. Patients with metastatic breast cancer (n = 97) subsequently treated with endocrine therapy were included in the analysis. Patients with AR/ER-high or -low groups were separated by median of AR/ER level in the cohort. The number of events (total deaths in each group) is indicated. Patients with lower AR/ER levels have a more favorable prognosis compared with patients who have higher AR/ER levels. E, Progression-free survival. F, Overall survival. The log-rank test indicates a significant difference between the survival curves.
Recombinant Full Length Human Ar, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant full length human ar/product/Creative BioMart
Average 92 stars, based on 1 article reviews
recombinant full length human ar - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
recombinant full-length human ar protein  (Creative BioMart)
90
Creative BioMart recombinant full-length human ar protein
Relative AR/ER expression in primary and metastatic ER+ breast cancers. A, Bar chart of the percentage of AR staining intensity in <t>ER</t> weak (+), intermediate (2+), and strong (3+) tumors in IHC cohort. The intensity of nuclei immunoreactivity was assessed semiquantitatively on a scale of 0 to 3 (none, weak, intermediate, and strong). B, Distribution of AR/ER in IHC cohort (n = 68). Expressions were quantified using IHC scores, positive cell percentage × intensity. C, Distribution of AR/ER in TCGA breast cancer cohort (n = 347). The reverse phase protein array was used to test AR and <t>ER</t> <t>protein</t> levels. D, Violin plot of AR/ER level in primary and metastatic breast cancer. Bars are presented as 25th percentile (bottom quartile), median, and 75th percentile (top quartile). AR/ER is higher in metastatic cancer than in primary cancer (primary vs. metastatic, median 0.047 vs. 0.689, unpaired two-tailed Student t test, P = 0.0001). E and F, Kaplan–Meier survival curves displaying the estimated survival probability for two different groups (AR/ER high vs. low) of metastatic breast cancer. Patients with metastatic breast cancer (n = 97) subsequently treated with endocrine therapy were included in the analysis. Patients with AR/ER-high or -low groups were separated by median of AR/ER level in the cohort. The number of events (total deaths in each group) is indicated. Patients with lower AR/ER levels have a more favorable prognosis compared with patients who have higher AR/ER levels. E, Progression-free survival. F, Overall survival. The log-rank test indicates a significant difference between the survival curves.
Recombinant Full Length Human Ar Protein, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant full-length human ar protein/product/Creative BioMart
Average 90 stars, based on 1 article reviews
recombinant full-length human ar protein - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
plasmid pcmv5-har encoding full-length ar (fl-ar)  (Addgene inc)
90
Addgene inc plasmid pcmv5-har encoding full-length ar (fl-ar)
Relative AR/ER expression in primary and metastatic ER+ breast cancers. A, Bar chart of the percentage of AR staining intensity in <t>ER</t> weak (+), intermediate (2+), and strong (3+) tumors in IHC cohort. The intensity of nuclei immunoreactivity was assessed semiquantitatively on a scale of 0 to 3 (none, weak, intermediate, and strong). B, Distribution of AR/ER in IHC cohort (n = 68). Expressions were quantified using IHC scores, positive cell percentage × intensity. C, Distribution of AR/ER in TCGA breast cancer cohort (n = 347). The reverse phase protein array was used to test AR and <t>ER</t> <t>protein</t> levels. D, Violin plot of AR/ER level in primary and metastatic breast cancer. Bars are presented as 25th percentile (bottom quartile), median, and 75th percentile (top quartile). AR/ER is higher in metastatic cancer than in primary cancer (primary vs. metastatic, median 0.047 vs. 0.689, unpaired two-tailed Student t test, P = 0.0001). E and F, Kaplan–Meier survival curves displaying the estimated survival probability for two different groups (AR/ER high vs. low) of metastatic breast cancer. Patients with metastatic breast cancer (n = 97) subsequently treated with endocrine therapy were included in the analysis. Patients with AR/ER-high or -low groups were separated by median of AR/ER level in the cohort. The number of events (total deaths in each group) is indicated. Patients with lower AR/ER levels have a more favorable prognosis compared with patients who have higher AR/ER levels. E, Progression-free survival. F, Overall survival. The log-rank test indicates a significant difference between the survival curves.
Plasmid Pcmv5 Har Encoding Full Length Ar (Fl Ar), supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasmid pcmv5-har encoding full-length ar (fl-ar)/product/Addgene inc
Average 90 stars, based on 1 article reviews
plasmid pcmv5-har encoding full-length ar (fl-ar) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
full length wild type ar plasmid pcmv har  (Addgene inc)
93
Addgene inc full length wild type ar plasmid pcmv har
Relative AR/ER expression in primary and metastatic ER+ breast cancers. A, Bar chart of the percentage of AR staining intensity in <t>ER</t> weak (+), intermediate (2+), and strong (3+) tumors in IHC cohort. The intensity of nuclei immunoreactivity was assessed semiquantitatively on a scale of 0 to 3 (none, weak, intermediate, and strong). B, Distribution of AR/ER in IHC cohort (n = 68). Expressions were quantified using IHC scores, positive cell percentage × intensity. C, Distribution of AR/ER in TCGA breast cancer cohort (n = 347). The reverse phase protein array was used to test AR and <t>ER</t> <t>protein</t> levels. D, Violin plot of AR/ER level in primary and metastatic breast cancer. Bars are presented as 25th percentile (bottom quartile), median, and 75th percentile (top quartile). AR/ER is higher in metastatic cancer than in primary cancer (primary vs. metastatic, median 0.047 vs. 0.689, unpaired two-tailed Student t test, P = 0.0001). E and F, Kaplan–Meier survival curves displaying the estimated survival probability for two different groups (AR/ER high vs. low) of metastatic breast cancer. Patients with metastatic breast cancer (n = 97) subsequently treated with endocrine therapy were included in the analysis. Patients with AR/ER-high or -low groups were separated by median of AR/ER level in the cohort. The number of events (total deaths in each group) is indicated. Patients with lower AR/ER levels have a more favorable prognosis compared with patients who have higher AR/ER levels. E, Progression-free survival. F, Overall survival. The log-rank test indicates a significant difference between the survival curves.
Full Length Wild Type Ar Plasmid Pcmv Har, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/full length wild type ar plasmid pcmv har/product/Addgene inc
Average 93 stars, based on 1 article reviews
full length wild type ar plasmid pcmv har - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
pcmv5-har encoding full-length ar (fl-ar)  (Addgene inc)
90
Addgene inc pcmv5-har encoding full-length ar (fl-ar)
Relative AR/ER expression in primary and metastatic ER+ breast cancers. A, Bar chart of the percentage of AR staining intensity in <t>ER</t> weak (+), intermediate (2+), and strong (3+) tumors in IHC cohort. The intensity of nuclei immunoreactivity was assessed semiquantitatively on a scale of 0 to 3 (none, weak, intermediate, and strong). B, Distribution of AR/ER in IHC cohort (n = 68). Expressions were quantified using IHC scores, positive cell percentage × intensity. C, Distribution of AR/ER in TCGA breast cancer cohort (n = 347). The reverse phase protein array was used to test AR and <t>ER</t> <t>protein</t> levels. D, Violin plot of AR/ER level in primary and metastatic breast cancer. Bars are presented as 25th percentile (bottom quartile), median, and 75th percentile (top quartile). AR/ER is higher in metastatic cancer than in primary cancer (primary vs. metastatic, median 0.047 vs. 0.689, unpaired two-tailed Student t test, P = 0.0001). E and F, Kaplan–Meier survival curves displaying the estimated survival probability for two different groups (AR/ER high vs. low) of metastatic breast cancer. Patients with metastatic breast cancer (n = 97) subsequently treated with endocrine therapy were included in the analysis. Patients with AR/ER-high or -low groups were separated by median of AR/ER level in the cohort. The number of events (total deaths in each group) is indicated. Patients with lower AR/ER levels have a more favorable prognosis compared with patients who have higher AR/ER levels. E, Progression-free survival. F, Overall survival. The log-rank test indicates a significant difference between the survival curves.
Pcmv5 Har Encoding Full Length Ar (Fl Ar), supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcmv5-har encoding full-length ar (fl-ar)/product/Addgene inc
Average 90 stars, based on 1 article reviews
pcmv5-har encoding full-length ar (fl-ar) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
plasmid encoding the human full-length ar  (VectorBuilder GmbH)
90
VectorBuilder GmbH plasmid encoding the human full-length ar
Relative AR/ER expression in primary and metastatic ER+ breast cancers. A, Bar chart of the percentage of AR staining intensity in <t>ER</t> weak (+), intermediate (2+), and strong (3+) tumors in IHC cohort. The intensity of nuclei immunoreactivity was assessed semiquantitatively on a scale of 0 to 3 (none, weak, intermediate, and strong). B, Distribution of AR/ER in IHC cohort (n = 68). Expressions were quantified using IHC scores, positive cell percentage × intensity. C, Distribution of AR/ER in TCGA breast cancer cohort (n = 347). The reverse phase protein array was used to test AR and <t>ER</t> <t>protein</t> levels. D, Violin plot of AR/ER level in primary and metastatic breast cancer. Bars are presented as 25th percentile (bottom quartile), median, and 75th percentile (top quartile). AR/ER is higher in metastatic cancer than in primary cancer (primary vs. metastatic, median 0.047 vs. 0.689, unpaired two-tailed Student t test, P = 0.0001). E and F, Kaplan–Meier survival curves displaying the estimated survival probability for two different groups (AR/ER high vs. low) of metastatic breast cancer. Patients with metastatic breast cancer (n = 97) subsequently treated with endocrine therapy were included in the analysis. Patients with AR/ER-high or -low groups were separated by median of AR/ER level in the cohort. The number of events (total deaths in each group) is indicated. Patients with lower AR/ER levels have a more favorable prognosis compared with patients who have higher AR/ER levels. E, Progression-free survival. F, Overall survival. The log-rank test indicates a significant difference between the survival curves.
Plasmid Encoding The Human Full Length Ar, supplied by VectorBuilder GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasmid encoding the human full-length ar/product/VectorBuilder GmbH
Average 90 stars, based on 1 article reviews
plasmid encoding the human full-length ar - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
full length human androgen receptor vector plenti6 3 ar gce2325  (Addgene inc)
93
Addgene inc full length human androgen receptor vector plenti6 3 ar gce2325
Relative AR/ER expression in primary and metastatic ER+ breast cancers. A, Bar chart of the percentage of AR staining intensity in <t>ER</t> weak (+), intermediate (2+), and strong (3+) tumors in IHC cohort. The intensity of nuclei immunoreactivity was assessed semiquantitatively on a scale of 0 to 3 (none, weak, intermediate, and strong). B, Distribution of AR/ER in IHC cohort (n = 68). Expressions were quantified using IHC scores, positive cell percentage × intensity. C, Distribution of AR/ER in TCGA breast cancer cohort (n = 347). The reverse phase protein array was used to test AR and <t>ER</t> <t>protein</t> levels. D, Violin plot of AR/ER level in primary and metastatic breast cancer. Bars are presented as 25th percentile (bottom quartile), median, and 75th percentile (top quartile). AR/ER is higher in metastatic cancer than in primary cancer (primary vs. metastatic, median 0.047 vs. 0.689, unpaired two-tailed Student t test, P = 0.0001). E and F, Kaplan–Meier survival curves displaying the estimated survival probability for two different groups (AR/ER high vs. low) of metastatic breast cancer. Patients with metastatic breast cancer (n = 97) subsequently treated with endocrine therapy were included in the analysis. Patients with AR/ER-high or -low groups were separated by median of AR/ER level in the cohort. The number of events (total deaths in each group) is indicated. Patients with lower AR/ER levels have a more favorable prognosis compared with patients who have higher AR/ER levels. E, Progression-free survival. F, Overall survival. The log-rank test indicates a significant difference between the survival curves.
Full Length Human Androgen Receptor Vector Plenti6 3 Ar Gce2325, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/full length human androgen receptor vector plenti6 3 ar gce2325/product/Addgene inc
Average 93 stars, based on 1 article reviews
full length human androgen receptor vector plenti6 3 ar gce2325 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
full length human androgen receptor vector plenti6 3 ar gc e2325  (Addgene inc)
93
Addgene inc full length human androgen receptor vector plenti6 3 ar gc e2325
Relative AR/ER expression in primary and metastatic ER+ breast cancers. A, Bar chart of the percentage of AR staining intensity in <t>ER</t> weak (+), intermediate (2+), and strong (3+) tumors in IHC cohort. The intensity of nuclei immunoreactivity was assessed semiquantitatively on a scale of 0 to 3 (none, weak, intermediate, and strong). B, Distribution of AR/ER in IHC cohort (n = 68). Expressions were quantified using IHC scores, positive cell percentage × intensity. C, Distribution of AR/ER in TCGA breast cancer cohort (n = 347). The reverse phase protein array was used to test AR and <t>ER</t> <t>protein</t> levels. D, Violin plot of AR/ER level in primary and metastatic breast cancer. Bars are presented as 25th percentile (bottom quartile), median, and 75th percentile (top quartile). AR/ER is higher in metastatic cancer than in primary cancer (primary vs. metastatic, median 0.047 vs. 0.689, unpaired two-tailed Student t test, P = 0.0001). E and F, Kaplan–Meier survival curves displaying the estimated survival probability for two different groups (AR/ER high vs. low) of metastatic breast cancer. Patients with metastatic breast cancer (n = 97) subsequently treated with endocrine therapy were included in the analysis. Patients with AR/ER-high or -low groups were separated by median of AR/ER level in the cohort. The number of events (total deaths in each group) is indicated. Patients with lower AR/ER levels have a more favorable prognosis compared with patients who have higher AR/ER levels. E, Progression-free survival. F, Overall survival. The log-rank test indicates a significant difference between the survival curves.
Full Length Human Androgen Receptor Vector Plenti6 3 Ar Gc E2325, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/full length human androgen receptor vector plenti6 3 ar gc e2325/product/Addgene inc
Average 93 stars, based on 1 article reviews
full length human androgen receptor vector plenti6 3 ar gc e2325 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


Relative AR/ER expression in primary and metastatic ER+ breast cancers. A, Bar chart of the percentage of AR staining intensity in ER weak (+), intermediate (2+), and strong (3+) tumors in IHC cohort. The intensity of nuclei immunoreactivity was assessed semiquantitatively on a scale of 0 to 3 (none, weak, intermediate, and strong). B, Distribution of AR/ER in IHC cohort (n = 68). Expressions were quantified using IHC scores, positive cell percentage × intensity. C, Distribution of AR/ER in TCGA breast cancer cohort (n = 347). The reverse phase protein array was used to test AR and ER protein levels. D, Violin plot of AR/ER level in primary and metastatic breast cancer. Bars are presented as 25th percentile (bottom quartile), median, and 75th percentile (top quartile). AR/ER is higher in metastatic cancer than in primary cancer (primary vs. metastatic, median 0.047 vs. 0.689, unpaired two-tailed Student t test, P = 0.0001). E and F, Kaplan–Meier survival curves displaying the estimated survival probability for two different groups (AR/ER high vs. low) of metastatic breast cancer. Patients with metastatic breast cancer (n = 97) subsequently treated with endocrine therapy were included in the analysis. Patients with AR/ER-high or -low groups were separated by median of AR/ER level in the cohort. The number of events (total deaths in each group) is indicated. Patients with lower AR/ER levels have a more favorable prognosis compared with patients who have higher AR/ER levels. E, Progression-free survival. F, Overall survival. The log-rank test indicates a significant difference between the survival curves.

Journal: Cancer research

Article Title: Pharmacological targeting of androgen receptor elicits context-specific effects in estrogen receptor-positive breast cancer

doi: 10.1158/0008-5472.CAN-22-1016

Figure Lengend Snippet: Relative AR/ER expression in primary and metastatic ER+ breast cancers. A, Bar chart of the percentage of AR staining intensity in ER weak (+), intermediate (2+), and strong (3+) tumors in IHC cohort. The intensity of nuclei immunoreactivity was assessed semiquantitatively on a scale of 0 to 3 (none, weak, intermediate, and strong). B, Distribution of AR/ER in IHC cohort (n = 68). Expressions were quantified using IHC scores, positive cell percentage × intensity. C, Distribution of AR/ER in TCGA breast cancer cohort (n = 347). The reverse phase protein array was used to test AR and ER protein levels. D, Violin plot of AR/ER level in primary and metastatic breast cancer. Bars are presented as 25th percentile (bottom quartile), median, and 75th percentile (top quartile). AR/ER is higher in metastatic cancer than in primary cancer (primary vs. metastatic, median 0.047 vs. 0.689, unpaired two-tailed Student t test, P = 0.0001). E and F, Kaplan–Meier survival curves displaying the estimated survival probability for two different groups (AR/ER high vs. low) of metastatic breast cancer. Patients with metastatic breast cancer (n = 97) subsequently treated with endocrine therapy were included in the analysis. Patients with AR/ER-high or -low groups were separated by median of AR/ER level in the cohort. The number of events (total deaths in each group) is indicated. Patients with lower AR/ER levels have a more favorable prognosis compared with patients who have higher AR/ER levels. E, Progression-free survival. F, Overall survival. The log-rank test indicates a significant difference between the survival curves.

Article Snippet: Recombinant full-length human AR and ERα protein ordered from Creative Biomart.

Techniques: Expressing, Staining, Protein Array, Two Tailed Test